Mean Percent PASI Improvement With Bimekizumab in Patients With Moderate to Severe Plaque Psoriasis: Pooled Results from Four Phase 3 3b Trials. J of Skin 2021, 5 (6), s55. https://doi.org/10.25251/skin.5.supp.55.